Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(†)

BACKGROUND: The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and progression-free survival (PFS) (HR = 0.793, P < 0.0005) compared with placebo + FOLFIRI for second-line metastatic colorectal carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T. W., Yang, L., Nasroulah, F., Tabernero, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091322/
https://www.ncbi.nlm.nih.gov/pubmed/27573561
http://dx.doi.org/10.1093/annonc/mdw402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091322/
https://www.ncbi.nlm.nih.gov/pubmed/27573561
http://dx.doi.org/10.1093/annonc/mdw402

Ejemplares similares